



MEMBERSHIP

May 16, 2025

Company name Shin Nippon Biomedical Laboratories, Ltd.  
Representative Ryoichi Nagata, Representative Chairman,  
President & CEO  
Listing TSE PRIME : ticker code 2395  
Inquiries Toshiyuki Iwata, Executive Officer, Head of  
Corporate Communications  
TEL +81 3 5565 6216

## (Corrections/Corrections of Numerical Data)

### Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)

Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, “the Company”) announces the corrections to the “Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)” released on May 8, 2025.

#### 1. Reason for corrections

It was discovered that there were errors in the “Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 (Under Japanese GAAP)”.

#### 2. Details of Corrections

Corrections are made to page 23 of “(Notes to segment information) 3. Information on the amounts of net sales, profit (loss), assets, liabilities, and other items by reportable segment” of “(5) Notes to consolidated financial statements”, shown with underlines as below.

(Before corrections)

Fiscal year ended March 31, 2025 (from April 1, 2024 to March 31, 2025)

(Thousands of yen)

	Reportable segments				
	CRO business	TR business	Medipolis business	US Property Management business	Subtotal
Net sales					
Net sales from external customers	31,514,523	54,161	470,398	45,980	32,085,063
Intersegment sales or transfer	80,587	-	94,536	-	175,124
Total	31,595,111	54,161	564,934	45,980	32,260,188
Segment profit (loss)	7,257,733	(3,680,520)	(422,318)	(60,500)	3,094,393
Segment assets	43,916,452	<u>2,334,875</u>	2,087,360	6,223,891	<u>54,562,580</u>
Other items					
Depreciation	1,956,418	51,592	182,550	43,294	2,233,856
Share of profit (loss) of entities accounted for using equity method	3,512,519	-	-	-	3,512,519
Increase in property, plant and equipment and intangible assets	<u>10,407,045</u>	216,781	68,983	<u>297,330</u>	10,990,140

(Thousands of yen)

	Other (Note 1)	Total	Adjustments (Note 2)	Amount recorded on the consolidated statement of income (Note 3)
Net sales				
Net sales from external customers	328,743	32,413,807	-	32,413,807
Intersegment sales or transfer	1,461,538	1,636,662	(1,636,662)	-
Total	1,790,281	34,050,470	(1,636,662)	32,413,807
Segment profit (loss)	(26,611)	3,067,781	(82,566)	2,985,215
Segment assets	3,046,649	<u>57,609,230</u>	<u>34,807,277</u>	92,416,508
Other items				
Depreciation	262,998	2,496,854	-	2,496,854
Share of profit (loss) of entities accounted for using equity method	663	3,513,182	-	3,513,182
Increase in property, plant and equipment and intangible assets	400,443	11,390,584	-	11,390,584

- (Notes) 1. The “Other” classification serves as a business segment not included in the reportable segments, and accordingly includes the construction and other businesses.
2. Segment profit (loss) adjustments amounting to negative ¥82,566 thousand consist of negative ¥31,538 thousand in elimination of intersegment transactions and ¥114,105 thousand in corporate expenses not allocated to a reportable segment. Corporate expenses are mainly general and administrative expenses, which are not attributable to the reportable segments. The adjustment amount of ¥34,807,277 thousand for segment assets is corporate assets that are not allocated to each reportable segment. Corporate assets consist mainly of surplus operating funds (cash and deposits, etc.) and long-term investment funds (investment securities, etc.).
3. Segment profit (loss) has been calculated upon adjusting operating profit in the consolidated statement of income.

(After corrections)

Fiscal year ended March 31, 2025 (from April 1, 2024 to March 31, 2025)

(Thousands of yen)

	Reportable segments				
	CRO business	TR business	Medipolis business	US Property Management business	Subtotal
Net sales					
Net sales from external customers	31,514,523	54,161	470,398	45,980	32,085,063
Intersegment sales or transfer	80,587	-	94,536	-	175,124
Total	31,595,111	54,161	564,934	45,980	32,260,188
Segment profit (loss)	7,257,733	(3,680,520)	(422,318)	(60,500)	3,094,393
Segment assets	43,916,452	<u>3,114,273</u>	2,087,360	6,223,891	<u>55,341,979</u>
Other items					
Depreciation	1,956,418	51,592	182,550	43,294	2,233,856
Share of profit (loss) of entities accounted for using equity method	3,512,519	-	-	-	3,512,519
Increase in property, plant and equipment and intangible assets	<u>7,731,073</u>	216,781	68,983	<u>2,973,302</u>	10,990,140

(Thousands of yen)

	Other (Note 1)	Total	Adjustments (Note 2)	Amount recorded on the consolidated statement of income (Note 3)
Net sales				
Net sales from external customers	328,743	32,413,807	-	32,413,807
Intersegment sales or transfer	1,461,538	1,636,662	(1,636,662)	-
Total	1,790,281	34,050,470	(1,636,662)	32,413,807
Segment profit (loss)	(26,611)	3,067,781	(82,566)	2,985,215
Segment assets	3,046,649	<u>58,388,629</u>	<u>34,027,878</u>	92,416,508
Other items				
Depreciation	262,998	2,496,854	-	2,496,854
Share of profit (loss) of entities accounted for using equity method	663	3,513,182	-	3,513,182
Increase in property, plant and equipment and intangible assets	400,443	11,390,584	-	11,390,584

- (Notes) 1. The “Other” classification serves as a business segment not included in the reportable segments, and accordingly includes the the construction and other businesses.
2. Segment profit (loss) adjustments amounting to negative ¥82,566 thousand consist of negative ¥31,538 thousand in elimination of intersegment transactions and ¥114,105 thousand in corporate expenses not allocated to a reportable segment. Corporate expenses are mainly general and administrative expenses, which are not attributable to the reportable segments. The adjustment amount of ¥34,027,878 thousand for segment assets is corporate assets that are not allocated to each reportable segment. Corporate assets consist mainly of surplus operating funds (cash and deposits, etc.) and long-term investment funds (investment securities, etc.).
3. Segment profit (loss) has been calculated upon adjusting operating profit in the consolidated statement of income.

END